PDF: Update on Drugs & Devices: May-June 2022

PDF Download: This update covers Nivolumab + Relatlimab-rmbw for IV use – Opdualag™ (Bristol-Myers Squibb), Sirolimus topical gel 0.2% – Hyftor™ (Nobelpharma America), Oral epinephrine – AQST-109 (Aquestive Therapeutics), and Bimekizumab for SC use – Bimzelx® (UCB Canada Inc.).